Jamie Daw is a Policy Analyst with the pharmaceutical policy research team at CHSPR. Jamie manages and conducts research on pressing issues relating to Canadian and international pharmaceutical policy. Her recent work has examined prenatal prescription drug utilization, the history and performance of public drug financing models, the media’s role in framing pharmaceutical policy issues, and the emergence of product listing agreements as a tool for pharmaceutical pricing. Jamie holds a B.H.Sc. (Hons) from McMaster University and an M.Sc. in Population and Public Health specializing in health care services and systems from the University of British Columbia.
 
Peer-Reviewed Publications:

• Morgan SG, Daw JR. 2012. Canadian pharmacare: looking back, looking forward. Healthcare Policy 8(1): 17-25.
• Daw JR, Morgan SG. 2012. Stitching the gaps in the Canadian public drug coverage patchwork? A review of provincial pharmacare policy changes 2000-2010. Health Policy 104(1): 19-26.
• Daw JR, Mintzes B, Law MR, Hanley GE, Morgan SG. 2012. Prescription drug use in pregnancy: a retrospective population-based study in British Columbia, Canada (2001-2006). Clinical Therapeutics 34(1): 239-249.
• Daw JR, Hanley GE, Greyson DG, Morgan SG. 2011. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiology and Drug Safety 20(9): 895-902.